- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04033978
Cerebral Impact of Cognitive Remediation for People Suffering From Schizophrenia (IMPACTRCS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Among cognitive deficits associated to schizophrenia, the jumping to conclusion bias is a frequent consequence of the decision making process alteration. This bias is characterized by a fast decision making when probabilistic judgments would be necessar.
Cognitive remediation aims at reducing the impact of cognitive deficits. The program that will be used in the present study focuses on the jump to conclusion bias. In schizophrenia, the positive impact of programs targeting such a bias, and more generally social cognition, has already been shown in numerous studies. However, despite the fact that jumping to conclusion is one of the main goals of these programs, their effects on decision making are poorly investigated in literature.
The program should impact decision making and reduce the jumping to conclusion bias. The benefits will probably be linked with a change in the P300 signal. They will probably appear earlier and with bigger amplitudes.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: BON Laura, Psychologue
- Phone Number: +33 04 26 73 85 32
- Email: laura.bon@ch-le-vinatier.fr
Study Contact Backup
- Name: VIAL Véronique
- Phone Number: +33 04.37915531
- Email: _recherche@ch-le-vinatier.fr
Study Locations
-
-
Rhône
-
Lyon, Rhône, France, 69006
- centre de réhabilitation - Hôpital le Vinatier
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- People suffering from schizophrenia given the DSM-5
- People aged from 18 to 45 years old
- French mother tongue
- Medicated with Aripiprazole
- Medication unchanged in the last month
- Stable symptomatology
- People consenting to the research.
Exclusion Criteria:
- Recent addiction (tabacco excluded)
- Neurologic disorders (vascular disorders, neurodegenerative disorders, infections…)
- Somatic medication having cerebral impact (such as corticoids)
- Pregnant women, guardianship people.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cognitive remediation arm
Participants will be enrolled in a cognitive remediation group.
The program will last 10 weeks and be composed of 10 participants.
This program is based on strategy learning and its aim is to reduce the jumping to conclusion phenomenon.
|
10 sessions dealing with emotion recognition, jumping to conclusion, attributional style.program
lasts 10 weeks
|
Active Comparator: Control group
Participants will be enrolled in an information control group.
They will receive information about psychosocial rehabilitation and recovery process.
The program lasts 10 weeks.
|
10 sessions dealing psychosocial rehabilitation, neuropsychological evaluation, stigmatization, recovery process and severe mental disorders in general.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Jumping to the conclusion
Time Frame: 12 weeks
|
The primary outcome will be modification before and after intervention of the correct response percentage.
It is obtained by measuring the amplitude of the waves P300 and N200 of the electroencephalogram.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Warwick-Edinburg mental well-being (WEMWBS)
Time Frame: 12 weeks
|
The outcome measure of mental well-being will be the score of scale modification before and after intervention.
It is a questionnaire that includes 14 items.
|
12 weeks
|
The positive and the negative symptoms (PANNS)
Time Frame: 12 weeks
|
The measure of the cognitive fonctioning will be the modification before and after intervention of the score obtained at the proposed neuropsychological evaluation ( excecutive, attentional and social)
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: FRANCK Nicolas, Professor, CH Le Vinatier
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-A00813-54
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Cognitive remediation
-
Queen's UniversityCompleted
-
Queen's UniversityPfizerCompleted
-
Yale UniversityCompletedCancer | Cancer of the ProstateUnited States
-
Fundació Sant Joan de DéuCompletedIndication for Modification of Patient Cognitive StatusSpain
-
VA Office of Research and DevelopmentRecruiting
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH); Columbia UniversityCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Queen's UniversityCompleted
-
Douglas Mental Health University InstituteMcGill University; Canadian Institutes of Health Research (CIHR)Recruiting
-
Gemma Garrido GarcíaCompleted
-
Institut BergoniéUniversity of Bordeaux; Association OncogiteRecruiting